All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
TRANSLATE
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View psoriasis and psoriatic arthritis content recommended for you
EADV Congress 2022
20 May 2023
Are you caught up with this?
#EADVCongress | During the 31st EADV Congress, we were pleased to speak to Christine Bundy. We asked, What should shared decision-making look like in the management of #psoriasis and #psoriaticarthritis?
https://t.co/YxQ7FHHRys
#EADVCongress | During the 31st EADV Congress, we were pleased to speak to Christine Bundy. We asked, What should shared decision-making look like in the management of #psoriasis and #psoriaticarthritis?
https://t.co/YxQ7FHHRys
16 Feb 2023
Have you watched this?
#EADVCongress |The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to @BundyC. We asked, What should shared decision-making look like in the management of psoriasis and psoriatic arthritis?
#psoriasis #psoriaticarthritis
https://t.co/YxQ7FHHRys
#EADVCongress |The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to @BundyC. We asked, What should shared decision-making look like in the management of psoriasis and psoriatic arthritis?
#psoriasis #psoriaticarthritis
https://t.co/YxQ7FHHRys
28 Oct 2022
#EADVCongress | Data were presented on the long-term efficacy of deucravacitinib and the occurrence of COVID-19-related adverse events in patients with plaque psoriasis.
#psoriasis #plaquepsoriasis
Read more here 👉 https://t.co/fmh0vkdVU2
#psoriasis #plaquepsoriasis
Read more here 👉 https://t.co/fmh0vkdVU2
21 Oct 2022
Is spesolimab a safe option for patients with GPP? Our latest article summarizes at safety data presented at #EADVcongress, including AEs and infection rates.
Read more here 👉 https://t.co/eTKbSN06r1
#psoriasis
Read more here 👉 https://t.co/eTKbSN06r1
#psoriasis
20 Oct 2022
#EADVCongress | 🎧 The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Paolo Gisondi and Jose-Manuel Carrascosa. We asked, Is a treatment goal of PASI100 appropriate in psoriasis management?
#psoriasis
Listen to our podcast here 👇
https://t.co/RC2bmqbWpq
#psoriasis
Listen to our podcast here 👇
https://t.co/RC2bmqbWpq
17 Oct 2022
#EADVCongress |The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to @BundyC. We asked, What should shared decision-making look like in the management of psoriasis and psoriatic arthritis?
#psoriasis #psoriaticarthritis
https://t.co/YxQ7FHIpo0
#psoriasis #psoriaticarthritis
https://t.co/YxQ7FHIpo0
11 Sept 2022
We hope you enjoyed following our live updates and congress coverage.
We covered the #EADVCongress from Milan, Italy, and virtually.
Keep an eye on our socials for post-congress key points and insights!
@eadv #medicalcongress #psoriasis
We covered the #EADVCongress from Milan, Italy, and virtually.
Keep an eye on our socials for post-congress key points and insights!
@eadv #medicalcongress #psoriasis
10 Sept 2022
Final day plenary session at lunchtime today was another busy one.
Thank you @eadv for a great #EADVcongress - we’ll be back next year to get the latest updates in #psoriasis
Thank you @eadv for a great #EADVcongress - we’ll be back next year to get the latest updates in #psoriasis
10 Sept 2022
CONGRESS #EADVcongress | Jonathan Shapiro spoke about a retrospective study that aimed to utilise a machine learning tool to identify undiagnosed PsA patients, 1-4 years prior to regular diagnosis.
10 Sept 2022
CONGRESS #EADVCongress |
Controversies: Maintenance of biologics treatment in #psoriasis complete responders:
Elke de Jong YES - dose reduction feasible & safe, not for all
Luigi Naldi NO - lifestyle interventions crucial, tailor treatments, early intervention trials needed
Controversies: Maintenance of biologics treatment in #psoriasis complete responders:
Elke de Jong YES - dose reduction feasible & safe, not for all
Luigi Naldi NO - lifestyle interventions crucial, tailor treatments, early intervention trials needed
10 Sept 2022
CONGRESS #EADVcongress | April W. Armstrong presented results from the 'Psoriasis and Beyond' study on the impact of Psoriatic disease on mental health. 60% of patients reported having mild PsO, 24% reported having moderate PsO, and 16% reported having severe PsO.
10 Sept 2022
CONGRESS #EADVcongress | Maja Mockenhaupt spoke about spesolimab safety in GPP, PPP and AD across 5 clinical trials. The safety profile of spesolimab across the trials was comparable to placebo, and frequency of AEs was similar across trials.
10 Sept 2022
CONGRESS #EADVcongress | Diamant Thaçim reported on COVID-19 related AEs in the Phase 3 POETYK trials. Of the the 153 patients recieving deucravacitinib, serious COVID-19-related AEs occurred in 43 patients, 13 of these patients with COVID-19 pneumonia.
10 Sept 2022
It’s the last day of the #EADVCongress.
Don’t miss out on our final live updates!
Sessions covered ?
▪️ Late breaking news in #psoriasis
▪️ Free communications in psoriasis
▪️ Controversies on the use of biologics during maintenance in complete responders
#medicalcongress
Don’t miss out on our final live updates!
Sessions covered ?
▪️ Late breaking news in #psoriasis
▪️ Free communications in psoriasis
▪️ Controversies on the use of biologics during maintenance in complete responders
#medicalcongress
10 Sept 2022
CONGRESS #EADVcongress | Early results from the Phase 3 COMFORT trial were presented by Kim Papp. Pts with moderate-to-severe plaque #psoriasis were given either piclidenoson 3mg BID, apremilast 30 mg BID, or placebo.
10 Sept 2022
CONGRESS #EADVcongress | Mark Lebwohl shared long-term efficacy results from the Phase 3 POETYK PSO study. The trial enrolled pts with moderate-to-severe plaque #psoriasis.
As observed, % of patients on deucravacitinib achieving PASI 75 at week 112 was 84.4%
As observed, % of patients on deucravacitinib achieving PASI 75 at week 112 was 84.4%
10 Sept 2022
CONGRESS #EADVcongress | Dr. Kim Papp reported results from the ongoing Phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials. Pts with #psoriaticarthritis and nail or plaque #psoriasis received risankizumab or placebo.
9 Sept 2022
CONGRESS #EADVcongress | Dr. Kim Papp reported on results from the first 28 weeks of a Phase 3 study comparing Ustekinumab Biosimilar (CT-P43) with Reference Ustekinumab (UST) in pts with moderate to severe plaque #psoriasis.
9 Sept 2022
CONGRESS #EADVcongress | Lawrence Eichenfield presented results from a Phase 2a study of PF-07038124, a phosphodiesterase-4 inhibitor, for use in plaque psoriasis or AD. Treated pts showed improvement in IGA response rate & reduction in PASI score, compared to the vehicle control
9 Sept 2022
CONGRESS #EADVCongress | Prof Christopher Griffiths @cemg70044533 gave a very informative talk about the @PsoriasisAtlas which aims to research the global epidemiology, better understand the economic impact, recognise comorbidities, and improve early diagnosis of #psoriasis
9 Sept 2022
The @psoriasis_hub is bringing you comprehensive updates as we continue our live coverage!
Sessions covered today:
▪️ Educational sessions on #psoriasis
▪️ Pediatric dermatology
▪️ The EADV/AAD joint session
▪️ Late breaking news in psoriasis
#EADVCongress #medicalcongress
Sessions covered today:
▪️ Educational sessions on #psoriasis
▪️ Pediatric dermatology
▪️ The EADV/AAD joint session
▪️ Late breaking news in psoriasis
#EADVCongress #medicalcongress
9 Sept 2022
CONGRESS #EADVCongress | Marieke Seyger gave an informative talk about paediatric #psoriasis. Seyger spoke about the predictive diagnostic criteria, such as a well-demarkated erythematous rash on the body, and a family history of psoriasis.
9 Sept 2022
CONGRESS #EADVCongress | Anna Belloni Fortina spoke about the use of biologics in paediatric patients. Treatment with biologic agents in general may require less laboratory monitoring compared to conventional therapies, but we should consider current evidence for use in children.
9 Sept 2022
CONGRESS #EADVCongress | Curdin Conrad spoke about how to select the appropriate therapy for each patient. Chosen therapy can depend on the inflammatory pathway of the psoriasis; IL23/IL17 in plaque PsO, IL36/IL1 in pustular PsO, and IFN-a in acute PsO.
9 Sept 2022
CONGRESS #EADVCongress | Paolo Gisondi spoke in depth about comorbidities of #psoriasis. Inflammation in #psoriasis can lead to occurrence of comorbidities, e.g progression of NAFLD.
9 Sept 2022
CONGRESS #EADVCongress | May El Hachem spoke about pediatric #psoriasis, including different clinical manifestations and comorbidities. In children, psoriasis can be associated with PsA, cardiovasular disorder, and metabolic syndrome, amongst other comorbidities.
9 Sept 2022
CONGRESS #EADVCongress | Jose-Manuel Carrascosa gave an insightful talk into the pathophysiology of #psoriasis, highlighting the importance of understanding innate immunity. Keratinocytes are the initiator of the innate immune response, and IL17/IL23 can be targets for therapy.
8 Sept 2022
Just about recovered from todays fantastic #EADVcongress sessions on #psoriasis and looking forward to covering more exciting presentations tomorrow!
8 Sept 2022
CONGRESS #EADVCongress | Controveries session on PASI100 as a treatment goal in #psoriasis treatment.
Jose-Manuel Carrascosa @UABBarcelona NO - ‘perfection’ not realistic, patients don’t need PASI100 to be happy
Luis puig YES - PASI100 not perfection, but minimum involvement
Jose-Manuel Carrascosa @UABBarcelona NO - ‘perfection’ not realistic, patients don’t need PASI100 to be happy
Luis puig YES - PASI100 not perfection, but minimum involvement
8 Sept 2022
CONGRESS #EADVCongress | Kristian Reich introduced the biologics vs biosimilars for #psoriasis session. Diamant Thaçi @UniLuebeck cited patient concern & availability in his pro biologics talk. Richard Warren @SalfordCO_NHS showed no difference in efficacy & AEs with biosimilars
8 Sept 2022
The @psoriasis_hub is covering the #EADVCongress virtually and in person!
Sessions covered today:
▪️ Reviews and updates on #psoriasis stratification, comorbidities, psychological burden, and treatment
▪️ Controversies around treatment goals and biologics vs biosimilars
Sessions covered today:
▪️ Reviews and updates on #psoriasis stratification, comorbidities, psychological burden, and treatment
▪️ Controversies around treatment goals and biologics vs biosimilars
8 Sept 2022
CONGRESS #EADVcongress | Eniko Sonkoly presented a talk on the role of small molecules in #psoriasis. Small molecules, which can be administered orally or topically, are able to target intracellular pathways.
8 Sept 2022
CONGRESS #EADVcongress | Nikolai Dyrberg Loft spoke about biosimilars in #psoriasis, including the approval procedures. Loft discussed the use of adalimumab biosimilars in Denmark, and the associated increase in uptake and reduction in cost.
8 Sept 2022
CONGRESS #EADVCongress | How to treat difficult-to-manage loacations? Tiago Torres addressed this problem, highlighting that conventional scoring systems fail to fully show the impact on QoL of patients. A lack of evidence-based data means there isn't a standardised treatment.
8 Sept 2022
CONGRESS #EADVcongress | @HBachelez spoke about the best ways to treat pustular psoriasis. Bachelez discusses the weak evidence for efficacy of using treatments approved for plaque #psoriasis for the treatment of GPP.
8 Sept 2022
A really busy #psoriasis session at #EADVCongress Excellent talks from the speakers and great to be here in person.
8 Sept 2022
CONGRESS #EADVcongress | Is there a place for classical systemic treatment in #psoriasis? Lluís Puig answered this question by discussing guidelines for topical vs systemic therapy. Puig also spoke about the time to achieve PASI 75 score, and time to relapse, in various therapies
8 Sept 2022
CONGRESS #EADVcongress | @carlefpaul spoke about the psychological burden of #psoriasis, including use of the PERMA model to measure happiness & wellbeing of patients. Patients with psoriasis can experience anxiety, depression, lower heuristic happiness, and a lower QoL.
8 Sept 2022
CONGRESS #EADVcongress | An interesting talk on comorbidities in #psoriasis by Antonio Costanzo. A comorbidity index shows the number of proteins shared between psoriasis and comorbidities, which in the future could be used to predict development of comorbidites.
8 Sept 2022
CONGRESS #EADVCongress | Kristian Reich gave an informative talk about pathophysiological stratification in #psoriasis, highlighting the importance of personalised medicine. Reich spoke about using genetic markers to predict response to drugs, and the risk of comorbidities.
7 Sept 2022
The #EADVCongress starts today!
The Psoriasis and Psoriatic Arthritis Hub is covering EADV virtually and in person!
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#medicalcongress #psoriasis
The Psoriasis and Psoriatic Arthritis Hub is covering EADV virtually and in person!
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#medicalcongress #psoriasis
7 Sept 2022
We will be providing live coverage of the #EADVCongress by sharing key content on #psoriasis and #psoriaticarthritis, as well as insights on new data and educational sessions. ?
Date: September 7–10
Location: Milan, Italy
@eadv #medicalcongress
Date: September 7–10
Location: Milan, Italy
@eadv #medicalcongress
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content